After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...

Neurogene Inc. (NGNE) has disclosed a new risk, in the Corporate Activity and Growth category.Don't Miss out on Research Tools:Discover the ...

Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

BMO Capital analyst Keith Tapper lowered the firm’s price target on Neurogene (NGNE) to $45 from $60 but keeps an Outperform rating on the ...

Shares of Neurogene Inc. (NASDAQ:NGNE – Get Free Report) have received a consensus recommendation of “Buy” from the nine ...

The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless ...

A serious adverse event in the New York biotech’s phase 1/2 trial of its Rett syndrome gene therapy puts a question mark over ...

Talks with the FDA haven’t gone according to plan. Seeking a streamlined pathway, Neurogene submitted a Regenerative Medicine ...

Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome ...

NEW YORK (AP) — NEW YORK (AP) — Neurogene Inc. (NGNE) on Monday reported a loss of $20.2 million in its third quarter. The New York-based company said it had a loss of $1.19 per share. The results ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter ...

Neurogene reported a patient experienced systemic hyperinflammatory syndrome during their Rett syndrome gene therapy trial. CEO Rachel McMinn confirmed the female patient is in critical condition. The ...